Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1

Conditions

Small Cell Lung Carcinoma 1Recurrence 1Lymphoma, Follicular 1

Interventions

Nivolumab 3pembrolizumab 2atezolizumab 2Rituximab 2Gemcitabine 2Cyclophosphamide 2venetoclax 1temsirolimus 1spartalizumab 1motexafin gadolinium 1mivebresib 1fludarabine 1enzalutamide 1entinostat 1durvalumab 1cc-486 1carfilzomib 1aldesleukin 1advexin 1Topotecan 1Therapeutics 1Thalidomide 1TTI-621 1Physical Therapy Modalities 1PF06821497 1Metformin 1Levofloxacin 1Leucovorin 1Itraconazole 1Interleukin-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × PF06821497 × Lymphoid × Clear all
NCT03460977 2026-06-05

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Pfizer

Phase 1 Recruiting
453 enrolled
LymphoidThoracic

Lymphoma, Follicular, Recurrence, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡